Canadian Cancer Trials Group Bulletins

Trial Management Group


Trail CCTG MEC.5: Step 1 closed to accrual

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma- SWOG S1404/CCTG MEC.5

The MEC.5 trial (SWOG S1404) has met its accrual target and is officially closed to new patient registration to STEP 1 as of Tuesday, August 15th, 2017. Please note that patients that have been registered to Step 1 on or before August 15, 2017 may continue to randomization (Step 2).